Cargando…
262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series
BACKGROUND: During the ongoing Coronavirus disease of 2019 (COVID-19) pandemic, there have been increasing reports of viral, bacterial and fungal co-infections. Two COVID-19-associated fungal infections (CFIs) have been identified – COVID-19 associated pulmonary aspergillosis (CAPA) and COVID-19 ass...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752877/ http://dx.doi.org/10.1093/ofid/ofac492.340 |
_version_ | 1784850836905525248 |
---|---|
author | Khatri, Akshay M Simkins, Jacques Sinha, Neeraj Phancao, Anita Ciancio, Gaetano Abbo, Lilian M Guerra, Giselle Natori, Yoichiro Anjan, Shweta |
author_facet | Khatri, Akshay M Simkins, Jacques Sinha, Neeraj Phancao, Anita Ciancio, Gaetano Abbo, Lilian M Guerra, Giselle Natori, Yoichiro Anjan, Shweta |
author_sort | Khatri, Akshay M |
collection | PubMed |
description | BACKGROUND: During the ongoing Coronavirus disease of 2019 (COVID-19) pandemic, there have been increasing reports of viral, bacterial and fungal co-infections. Two COVID-19-associated fungal infections (CFIs) have been identified – COVID-19 associated pulmonary aspergillosis (CAPA) and COVID-19 associated mucormycosis (CAM), but incidence and occurrence in solid organ transplant recipients (SOTRs) is limited. We describe our experience with CFIs in SOTRs with COVID-19. METHODS: In a single center retrospective study at a large volume transplant center in South Florida, USA, we included adult SOTRs (≥18 years) diagnosed with COVID-19 between March 1(st) 2020 and January 31(st) 2022, with subsequent diagnosis of CFI. We collected information related to demographics, comorbidities, COVID-19 diagnosis and therapeutics, and CFI diagnostics and management. Data obtained was analyzed descriptively. RESULTS: We identified 612 SOTRs with COVID-19, of which 23 (3.8%) were diagnosed with CFIs. The patients were predominantly male (17/23, 73.9%), with median age of 59 years (range 43-79) [Table 1]. Twenty (86.9%) were kidney transplant recipients. Majority of SOTRs had lymphopenia (18/23, 78.3%) with elevated inflammatory markers at time of COVID-19 diagnosis. They received most commonly remdesivir and corticosteroids for COVID-19, with 22 (95.6%) needing intensive care unit admission and 19 (82.6%) needing continuous renal replacement therapy. CFIs were diagnosed at median 21 days (range, 3-161) after initial COVID-19 diagnosis. Probable CAPA was diagnosed in most patients (16/23, 69.6%), with CAM noted in 1 patient [Table 2]. 34.8% (8/23) had specific fungal species identified, with elevated fungal markers noted in 95.6% (22/23). Concurrent or prior cytomegalovirus DNAemia was noted in 26.1% (6/23). Patients were followed for median 70 days (range, 19-572), with median hospitalization duration 56 days (range, 7-204). Mortality was noted in 73.9% (17/23). [Figure: see text] [Figure: see text] CONCLUSION: Fungal co-infections were noted in a small proportion of our SOTRs, with poor outcomes. Transplant physicians should have a high suspicion for early diagnosis and treatment of CFI. Further studies are needed to determine predictors for CFI and role for anti-fungal prophylaxis. DISCLOSURES: All Authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-9752877 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97528772022-12-16 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series Khatri, Akshay M Simkins, Jacques Sinha, Neeraj Phancao, Anita Ciancio, Gaetano Abbo, Lilian M Guerra, Giselle Natori, Yoichiro Anjan, Shweta Open Forum Infect Dis Abstracts BACKGROUND: During the ongoing Coronavirus disease of 2019 (COVID-19) pandemic, there have been increasing reports of viral, bacterial and fungal co-infections. Two COVID-19-associated fungal infections (CFIs) have been identified – COVID-19 associated pulmonary aspergillosis (CAPA) and COVID-19 associated mucormycosis (CAM), but incidence and occurrence in solid organ transplant recipients (SOTRs) is limited. We describe our experience with CFIs in SOTRs with COVID-19. METHODS: In a single center retrospective study at a large volume transplant center in South Florida, USA, we included adult SOTRs (≥18 years) diagnosed with COVID-19 between March 1(st) 2020 and January 31(st) 2022, with subsequent diagnosis of CFI. We collected information related to demographics, comorbidities, COVID-19 diagnosis and therapeutics, and CFI diagnostics and management. Data obtained was analyzed descriptively. RESULTS: We identified 612 SOTRs with COVID-19, of which 23 (3.8%) were diagnosed with CFIs. The patients were predominantly male (17/23, 73.9%), with median age of 59 years (range 43-79) [Table 1]. Twenty (86.9%) were kidney transplant recipients. Majority of SOTRs had lymphopenia (18/23, 78.3%) with elevated inflammatory markers at time of COVID-19 diagnosis. They received most commonly remdesivir and corticosteroids for COVID-19, with 22 (95.6%) needing intensive care unit admission and 19 (82.6%) needing continuous renal replacement therapy. CFIs were diagnosed at median 21 days (range, 3-161) after initial COVID-19 diagnosis. Probable CAPA was diagnosed in most patients (16/23, 69.6%), with CAM noted in 1 patient [Table 2]. 34.8% (8/23) had specific fungal species identified, with elevated fungal markers noted in 95.6% (22/23). Concurrent or prior cytomegalovirus DNAemia was noted in 26.1% (6/23). Patients were followed for median 70 days (range, 19-572), with median hospitalization duration 56 days (range, 7-204). Mortality was noted in 73.9% (17/23). [Figure: see text] [Figure: see text] CONCLUSION: Fungal co-infections were noted in a small proportion of our SOTRs, with poor outcomes. Transplant physicians should have a high suspicion for early diagnosis and treatment of CFI. Further studies are needed to determine predictors for CFI and role for anti-fungal prophylaxis. DISCLOSURES: All Authors: No reported disclosures. Oxford University Press 2022-12-15 /pmc/articles/PMC9752877/ http://dx.doi.org/10.1093/ofid/ofac492.340 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstracts Khatri, Akshay M Simkins, Jacques Sinha, Neeraj Phancao, Anita Ciancio, Gaetano Abbo, Lilian M Guerra, Giselle Natori, Yoichiro Anjan, Shweta 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series |
title | 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series |
title_full | 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series |
title_fullStr | 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series |
title_full_unstemmed | 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series |
title_short | 262. COVID-19 associated fungal co-infections in Solid Organ Transplant Recipients: A single center case series |
title_sort | 262. covid-19 associated fungal co-infections in solid organ transplant recipients: a single center case series |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752877/ http://dx.doi.org/10.1093/ofid/ofac492.340 |
work_keys_str_mv | AT khatriakshaym 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT simkinsjacques 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT sinhaneeraj 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT phancaoanita 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT cianciogaetano 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT abbolilianm 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT guerragiselle 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT natoriyoichiro 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries AT anjanshweta 262covid19associatedfungalcoinfectionsinsolidorgantransplantrecipientsasinglecentercaseseries |